R&D | March 10, 2026
UK pushes space-made medicines from orbit to patients with new support package
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
This study evaluated a difficult-to-treat Crohn's disease patient population
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Subscribe To Our Newsletter & Stay Updated
